



PROVIDING ANSWERS FOR CANCER PATIENTS

Press release
11 March, 2021

Curasight's presentation at Økonomisk Ugebrev Life Science Investor Conference is now available

Curasigt A/S by CEO Ulrich Krasilnikoff presented at Økonomisk Ugebrev's Life Science Investor Conference yesterday. Due to the Covid-19 restrictions the presentation was recorded and is now available [here](#) (in Danish only).

Økonomisk Ugebrev Life Science conveys the potential of Nordic equities in the BioTech and pharmaceutical sectors and brings analyzes of the 100 largest Nordic shares in the biotech and pharmaceutical sector. Analyzes are prepared by analysts with decades of experience.

The event was moderated by Økonomisk Ugebrev Life Science's analysts, Steen Albrechtsen, Morten Larsen and Lars Hatholt.

The film in the presentation is also available with Swedish subtitles [here](#)

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.